Definitive Healthcare Corp. (NASDAQ:DH – Get Free Report) has received an average rating of “Reduce” from the ten ratings firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $1.47.
A number of research firms have recently weighed in on DH. Bank of America restated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a report on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a report on Monday, August 31st. BTIG Research reiterated a “neutral” rating on shares of Definitive Healthcare in a report on Friday, September 4th. Morgan Stanley lowered their price target on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, September 13th.
Check Out Our Latest Stock Analysis on Definitive Healthcare
Institutional Trading of Definitive Healthcare
Definitive Healthcare Stock Down 0.4%
DH stock opened at $0.98 on Friday. The stock’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $0.88. The company has a market cap of $104.22 million, a P/E ratio of -0.61, a price-to-earnings-growth ratio of 12.09 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86. Definitive Healthcare has a fifty-two week low of $0.61 and a fifty-two week high of $3.12.
Definitive Healthcare (NASDAQ:DH – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%. The firm had revenue of $55.20 million during the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, research analysts expect that Definitive Healthcare will post 0.06 earnings per share for the current fiscal year.
About Definitive Healthcare
Definitive Healthcare Corp. is a healthcare commercial intelligence company that provides data, analytics and software to help organizations understand the healthcare market. Its platform is designed to support decision-making across areas such as sales and marketing, market access, provider network strategy, competitive intelligence and healthcare operations.
The company’s products combine information on healthcare providers, hospitals, health systems, medical groups, payers, procedures and related market activity.
Featured Articles
- Five stocks we like better than Definitive Healthcare
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
